122 related articles for article (PubMed ID: 15059912)
1. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen.
Kasuya H; Pawlik TM; Mullen JT; Donahue JM; Nakamura H; Chandrasekhar S; Kawasaki H; Choi E; Tanabe KK
Cancer Res; 2004 Apr; 64(7):2561-7. PubMed ID: 15059912
[TBL] [Abstract][Full Text] [Related]
2. Regulation of herpes simplex virus 1 replication using tumor-associated promoters.
Mullen JT; Kasuya H; Yoon SS; Carroll NM; Pawlik TM; Chandrasekhar S; Nakamura H; Donahue JM; Tanabe KK
Ann Surg; 2002 Oct; 236(4):502-12; discussion 512-3. PubMed ID: 12368679
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
Kurihara T; Brough DE; Kovesdi I; Kufe DW
J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
[TBL] [Abstract][Full Text] [Related]
4. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
Doloff JC; Jounaidi Y; Waxman DJ
Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
[TBL] [Abstract][Full Text] [Related]
5. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter.
Chen L; Chen D; Manome Y; Dong Y; Fine HA; Kufe DW
J Clin Invest; 1995 Dec; 96(6):2775-82. PubMed ID: 8675647
[TBL] [Abstract][Full Text] [Related]
7. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
11. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
12. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model.
Gupta VK; Park JO; Kurihara T; Koons A; Mauceri HJ; Jaskowiak NT; Kufe DW; Weichselbaum RR; Posner MC
Gene Ther; 2003 Feb; 10(3):206-12. PubMed ID: 12571627
[TBL] [Abstract][Full Text] [Related]
13. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
Chen RF; Li ZH; Pan QH; Zhou JJ; Tang QB; Yu FY; Zhou QB; Wang J; Chen JS
Pancreatology; 2007; 7(5-6):505-13. PubMed ID: 17912014
[TBL] [Abstract][Full Text] [Related]
14. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
Liu X; He B
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
[TBL] [Abstract][Full Text] [Related]
15. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
16. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
[TBL] [Abstract][Full Text] [Related]
17. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
20. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
